Runners Hit Wall With Weight-Loss Drugs

The increasing popularity of weight-loss drugs, including GLP-1s, is creating a complex scenario for endurance athletes. Runners are reporting significant challenges, such as severe nausea and an inability to maintain adequate energy intake, directly impacting their race performance. Experts express concern that these medications, which suppress appetite, can lead to low energy availability, a condition that poses health risks like reduced bone density and weakened immunity.

While some athletes attempt to manage side effects through dosage adjustments or timing strategies, medical professionals caution against altering prescribed use. Research on the long-term effects of GLP-1s on endurance performance remains limited, with varying individual experiences reported. Some runners successfully adapt and continue training, while others find the adverse effects too detrimental, ultimately discontinuing the medication.